American Society of Hematology 2019 guidelines for immune thrombocytopenia
Top Cited Papers
Open Access
- 9 December 2019
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 3 (23), 3829-3866
- https://doi.org/10.1182/bloodadvances.2019000966
Abstract
Background: Despite an increase in the number of therapies available to treat patients with immune thrombocytopenia (ITP), there are minimal data from randomized trials to assist physicians with the management of patients. Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the management of ITP. Methods: In 2015, ASH formed a multidisciplinary guideline panel that included 8 adult clinical experts, 5 pediatric clinical experts, 2 methodologists with expertise in ITP, and 2 patient representatives. The panel was balanced to minimize potential bias from conflicts of interest. The panel reviewed the ASH 2011 guideline recommendations and prioritized questions. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including evidence-to-decision frameworks, to appraise evidence (up to May 2017) and formulate recommendations. Results: The panel agreed on 21 recommendations covering management of ITP in adults and children with newly diagnosed, persistent, and chronic disease refractory to first-line therapy who have non-life-threatening bleeding. Management approaches included: observation, corticosteroids, IV immunoglobulin, anti-D immunoglobulin, rituximab, splenectomy, and thrombopoietin receptor agonists. Conclusions: There was a lack of evidence to support strong recommendations for various management approaches. In general, strategies that avoided medication side effects were favored. A large focus was placed on shared decision-making, especially with regard to second-line therapy. Future research should apply standard corticosteroid-dosing regimens, report patient-reported outcomes, and include cost-analysis evaluations.This publication has 204 references indexed in Scilit:
- Effects of Rapamycin Combined with Low Dose Prednisone in Patients with Chronic Immune ThrombocytopeniaJournal of Immunology Research, 2013
- Single course of high dose dexamethasone is more effective than conventional prednisolone therapy in the treatment of primary newly diagnosed immune thrombocytopeniaDARU Journal of Pharmaceutical Sciences, 2012
- Rituximab for Children with Immune Thrombocytopenia: A Systematic ReviewPLOS ONE, 2012
- The French Gaucher’s disease registry: clinical characteristics, complications and treatment of 562 patientsOrphanet Journal of Rare Diseases, 2012
- The Vexing Problem of Guidelines and Conflict of Interest: A Potential SolutionAnnals of Internal Medicine, 2010
- Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 casesBlood, 2009
- The ITP syndrome: pathogenic and clinical diversityBlood, 2009
- Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpuraBlood, 2008
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Single dose of anti-D immune globulin at 75μg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in childrenThe Journal of Pediatrics, 2006